Engineered immune cells take aim at rare blood cancer

NCT ID NCT04083495

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new approach for people with peripheral T-cell lymphoma that has come back or not responded to standard treatments. Researchers take a patient's own immune T-cells, modify them in the lab to recognize and attack cancer cells carrying the CD30 protein, and infuse them back. Before the infusion, patients receive chemotherapy to prepare their bodies. The goal is to see if this treatment is safe and can help control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD30-targeting CAR T-cells (ATLCAR.CD30) plus chemotherapy (bendamustine, fludarabine, cyclophosphamide)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat peripheral T-cell lymphoma, potentially improving disease control and survival.
What could go wrong: This is a small, early-phase trial (20 participants) focused on safety and feasibility. The treatment may not work for everyone and carries risks like cytokine release syndrome, infection, and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Wake Forest Baptist Medical Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.